A survey of Australian public attitudes towards funding of high cost cancer medicines
Author
Abstract
Suggested Citation
DOI: 10.1016/j.healthpol.2020.12.002
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Jennifer A. Whitty & Julie Ratcliffe & Gang Chen & Paul A. Scuffham, 2014. "Australian Public Preferences for the Funding of New Health Technologies," Medical Decision Making, , vol. 34(5), pages 638-654, July.
- Frank R. Lichtenberg, 2017. "The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia," The Economic Record, The Economic Society of Australia, vol. 93(302), pages 353-378, September.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Marta Trapero-Bertran & Beatriz Rodríguez-Martín & Julio López-Bastida, 2019. "What attributes should be included in a discrete choice experiment related to health technologies? A systematic literature review," PLOS ONE, Public Library of Science, vol. 14(7), pages 1-15, July.
- Lesley Chim & Glenn Salkeld & Patrick Kelly & Wendy Lipworth & Dyfrig A Hughes & Martin R Stockler, 2017. "Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-24, March.
- Denise Doiron & Hong Il Yoo, 2020. "Stated preferences over job characteristics: A panel study," Canadian Journal of Economics/Revue canadienne d'économique, John Wiley & Sons, vol. 53(1), pages 43-82, February.
- Soekhai, V. & Donkers, B. & Levitan, B. & de Bekker-Grob, E.W., 2021. "Case 2 best-worst scaling: For good or for bad but not for both," Journal of choice modelling, Elsevier, vol. 41(C).
- Whitty, Jennifer A. & Littlejohns, Peter, 2015. "Social values and health priority setting in Australia: An analysis applied to the context of health technology assessment," Health Policy, Elsevier, vol. 119(2), pages 127-136.
- Tatenda T Yemeke & Elizabeth E Kiracho & Aloysius Mutebi & Rebecca R Apolot & Anthony Ssebagereka & Daniel R Evans & Sachiko Ozawa, 2020. "Health versus other sectors: Multisectoral resource allocation preferences in Mukono district, Uganda," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-15, July.
- Soto, José R. & Adams, Damian C. & Escobedo, Francisco J., 2016. "Landowner attitudes and willingness to accept compensation from forest carbon offsets: Application of best–worst choice modeling in Florida USA," Forest Policy and Economics, Elsevier, vol. 63(C), pages 35-42.
- Lichtenberg Frank R., 2018.
"The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis,"
Forum for Health Economics & Policy, De Gruyter, vol. 21(2), pages 1-20, December.
- Frank R. Lichtenberg, 2019. "The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis," CESifo Working Paper Series 7559, CESifo.
- Nicolas Krucien & Verity Watson & Mandy Ryan, 2017. "Is Best–Worst Scaling Suitable for Health State Valuation? A Comparison with Discrete Choice Experiments," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1-16, December.
- Gu, Yuanyuan & Lancsar, Emily & Ghijben, Peter & Butler, James RG & Donaldson, Cam, 2015. "Attributes and weights in health care priority setting: A systematic review of what counts and to what extent," Social Science & Medicine, Elsevier, vol. 146(C), pages 41-52.
- Aizaki, Hideo & Fogarty, James, 2019. "An R package and tutorial for case 2 best–worst scaling," Journal of choice modelling, Elsevier, vol. 32(C), pages 1-1.
- Qinxin Guo & Junyi Shen, 2019. "An Empirical Comparison Between Discrete Choice Experiment and Best-worst Scaling: A Case Study of Mobile Payment Choice," Discussion Paper Series DP2019-14, Research Institute for Economics & Business Administration, Kobe University.
More about this item
Keywords
Health equity; Access to health care; Health insurance; Cancer; Health care technology; High-cost medicines;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:125:y:2021:i:3:p:327-334. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.